阿莫奈韋

化合物

阿莫奈韋INN:amenamevir)是一種用於治療帶狀疱疹抗病毒藥物

阿莫奈韋
臨床資料
商品名英語Drug nomenclatureAmenalief
其他名稱ASP-2151, ASP2151
ATC碼
法律規範狀態
法律規範
  • 處方藥(-only)
識別資訊
  • N-(2,6-Dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide
CAS號841301-32-4
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C24H26N4O5S
摩爾質量482.56 g·mol−1
3D模型(JSmol英語JSmol
  • Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1
  • InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)
  • Key:MNHNIVNAFBSLLX-UHFFFAOYSA-N

它充當帶狀疱疹病毒解旋酶-引物酶複合物英語Helicase–primase complex的抑制劑。[1][2]阿莫奈韋於2017年在日本獲批用於治療帶狀疱疹。[3]

參考資料

  1. ^ Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study. The Journal of Dermatology. November 2017, 44 (11): 1219–1227. PMC 5697646 . PMID 28681394. doi:10.1111/1346-8138.13948. 
  2. ^ Yajima M, Yamada H, Takemoto M, Daikoku T, Yoshida Y, Long T, et al. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor. Antiviral Research. March 2017, 139: 95–101. PMID 28027917. S2CID 43813287. doi:10.1016/j.antiviral.2016.12.008. 
  3. ^ Maruho Receives Manufacturing and Marketing Approval for Anti-Herpes Virus Agent "Amenalief® Tab. 200mg" in Japan (新聞稿). evaluategroup.com. July 3, 2017.